Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selective lymph node radiotherapy versus involved-field radiotherapy with concurrent S-1 and cisplatin for locally advanced esophageal squamous cell carcinoma
ChiCTR-TRC-13003547Phase 3Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Local-regional failure-free survival. Started Sep 2013; status: recruiting.
02
Drugs
tegafurcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-TRC-13003547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-13003547.